Expression of chemokine CXCL16 and its significance in breast cancer

doi:10.3877/cma. j. issn.1674-0807.2014.06.003

Abstract

Abstract:

Objective

To explore the expression of chemokine CXCL16 in human breast cancer and its clinical significance.

Methods

The tissue samples were collected from 94 cases of invasive breast cancer,20 cases of carcinoma in situ and 20 cases of breast benign lesions in Shenzhen Maternity and Child Healthcare Hospital from March 2012 to December 2013. The expressions of CXCL16 protein in samples were detected by immunohistochemical method. The relationships between the expression of CXCL16 and the clinicopathological characteristics of breast cancer patients including patients’ age, tumor size, histological grade, TNM stage and lymph node metastasis status were also analyzed. The data was processed using χ² test and rank sum test.

Results

The expression of CXCL16 protein was statistically different among invasive breast cancer group,carcinoma in situ group and benign lesion group (χ² =22.058,P=0.000). CXCL16 protein expression in invasive breast cancer was significantly higher than that in carcinoma in situ or in benign lesions (P=0.007,0.000). CXCL16 protein expression showed a statistical difference among invasive breast cancer patients with different tumor sizes, TNM stages and with or without lymph node metastasis (Z=-2.013,-2.166,-2.222;P=0.035,0.030,0.026), but no significant difference was observed between different age groups and between the patients with different histological grades (Z=-0.418, P=0.676; χ²=0.011,P=0.995).

Conclusion

CXCL16 may play a certain role in the development and metastasis of breast cancer.

Key words: Breast neoplasms, Chemotactic factors, CXCL16

Hongping Tang, Fang Liu, Guoyan Chen, Xiangyu Lu, Yingying Chen, Li Huang. Expression of chemokine CXCL16 and its significance in breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2014, 08(06): 391-395.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2014.06.003

https://zhrxbzz.cma-cmc.com.cn/EN/Y2014/V08/I06/391

Figures/Tables 3

References 26

[1]	Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumors of the breast [M]. 4th ed. Lyon: IARC Press, 2012,14-16.
[2]	汤红平,谢闺娥,黄犁,等. 106 例青年女性乳腺癌临床病理特点的回顾性分析[J/CD]. 中华乳腺病杂志:电子版,2013,7(6):28-31.
[3]	Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity [J]. Immunity, 2000, 12(2):121-127.
[4]	刘芳. CXCL16/CXCR6 与炎症性疾病[J]. 国际病理科学与临床杂志,2010,30(5):426-430..
[5]	Darash-Yahana M, Gillespie JW, Hewitt SM, et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers [J]. PLoS One,2009,4(8): e6695.
[6]	Kume N. New oxidized LDL receptors and their functions in atherogenesis [ J]. Nihon Ronen Igakkai Zasshi, 2002,39(3):264-267.
[7]	Matloubian M, David A, Engel S, et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo [J]. Nat Immunol,2000,1(4):298-304.
[8]	Shimaoka T, Nakayama T, Kume N, et al. Cutting edge: SRPSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain[J]. J Immunol,2003,171(4):1647-1651.
[9]	Shimaoka T, Nakayama T, Fukumoto N, et al. Cell surfaceanchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells [J]. J Leukoc Biol,2004,75(2):267-274.
[10]	Hattermann K, Ludwig A, Gieselmann V, et al. The chemokine CXCL16 induces migration and invasion of glial precursor cells via its receptor CXCR6 [J]. Mol Cell Neurosci,2008,39(1):133-141.
[11]	Zhuge X, Murayama T, Arai H, et al. CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells[J]. Biochem Biophys Res Commun,2005,331(4):1295-1300.
[12]	Huang Y, Zhu XY, Du MR, et al. Chemokine CXCL16, a scavenger receptor, induces proliferation and invasion of firsttrimester human trophoblast cells in an autocrine manner [J].Hum Reprod,2006,21(4):1083-1091.
[13]	Wågsäter D, Hugander A, Dimberg J. Expression of CXCL16 in human rectal cancer [J]. Int J Mol Med, 2004, 14(1):65-69.
[14]	Wente MN, Gaida MM, Mayer C, et al. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma [J]. Int J Oncol,2008,33(2):297-308.
[15]	Gao Q, Zhao YJ, Wang XY, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma [J]. Cancer Res,2012,72(14):3546-3556.
[16]	Lee JT, Lee SD, Lee JZ, et al. Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer [J]. Oncol Lett,2013,5(1):229-235.
[17]	Guo L, Cui ZM, Zhang J, et al. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma [J]. Chin J Cancer,2011,30(5):336-343.
[18]	周雯慧,胡卫东,徐闻博. 趋化因子及其受体CXCL16 /CXCR6 体外促前列腺癌增殖、侵袭作用[J]. 武汉大学学报(医学版),2010,31(4):479-482.
[19]	Wang J, Lu Y, Wang J,et al. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway [J]. Cancer Res, 2008, 68(24): 10 367-10 376.
[20]	Wang YH, Dong YY, Wang WM, et al. Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-kappaB pathways induced by paracrine cytokines [J].J Exp Clin Cancer Res,2013,32(1):51.
[21]	Huang Y,Zhang J,Cui ZM,et al. Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer [J]. Chin J Cancer,2013,32(5):289-296.
[22]	Hattermann K, Held-Feindt J, Ludwig A, et al. The CXCL16-CXCR6 chemokine axis in glial tumors [J]. J Neuroimmunol,2013,260(1-2):47-54.
[23]	Deutsch AJ, Steinbauer E, Hofmann NA, et al. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma [J]. Mod Pathol,2013,26(2):182-194.
[24]	Lin S, Sun L, Hu J, et al. Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia [J]. Cancer Lett,2009,279(1):108-117.
[25]	方业颖,雷倩倩,李燕,等. 非分泌型CXCL16 在乳腺癌细胞系中的表达及对其生物学特性的影响[J]. 四川大学学报(医学版),2013,44(4):522-525,530.
[26]	Matsumura S, Wang B, Kawashima N, et al. Radiationinduced CXCL16 release by breast cancer cells attracts effector T cells [J]. J Immunol,2008,181(5):3099-3107.

病变类型	例数	CXCL16(例)
病变类型	例数	-	+	++
浸润性乳腺癌^ab	94	9	15	70
乳腺原位癌^c	20	2	10	8
乳腺良性病变	20	5	11	4
χ²值	22.058
P值	0.000

病变类型	例数	CXCL16(例)
病变类型	例数	-	+	++
浸润性乳腺癌^ab	94	9	15	70
乳腺原位癌^c	20	2	10	8
乳腺良性病变	20	5	11	4
χ²值	22.058
P值	0.000

临床病理特征	例数	CXCL16(例)			检验值	P值
临床病理特征	例数	-	+	++	检验值	P值
年龄					-0.418	0.676
≤50.0岁	51	5	7	39
＞50.0岁	43	4	8	31
肿瘤直径					-2.013	0.035
≤2 cm	45	6	10	29
＞2 cm	49	3	5	41
组织学分级					0.011^a	0.995
Ⅰ	20	2	3	15
Ⅱ	47	4	8	35
Ⅲ	27	3	4	20
TNM分期					-2.166	0.030
Ⅰ/Ⅱ	48	6	11	31
Ⅲ/Ⅳ	46	3	4	39
淋巴结转移					-2.222	0.026
无	45	7	9	29
有	49	2	6	41

临床病理特征	例数	CXCL16(例)			检验值	P值
临床病理特征	例数	-	+	++	检验值	P值
年龄					-0.418	0.676
≤50.0岁	51	5	7	39
＞50.0岁	43	4	8	31
肿瘤直径					-2.013	0.035
≤2 cm	45	6	10	29
＞2 cm	49	3	5	41
组织学分级					0.011^a	0.995
Ⅰ	20	2	3	15
Ⅱ	47	4	8	35
Ⅲ	27	3	4	20
TNM分期					-2.166	0.030
Ⅰ/Ⅱ	48	6	11	31
Ⅲ/Ⅳ	46	3	4	39
淋巴结转移					-2.222	0.026
无	45	7	9	29
有	49	2	6	41

Please choose a citation manager

Content to export